Premium
Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission
Author(s) -
Narula Neeraj,
Aruljothy Achuthan,
Alshahrani AbdulAziz,
Fadida Ma’ayan,
AlSaedi Mona,
Marshall John K.,
Rubin David T.,
Christensen Britt
Publication year - 2020
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.16147
Subject(s) - medicine , ulcerative colitis , complete remission , spontaneous remission , gastroenterology , colitis , pathology , disease , chemotherapy , alternative medicine
Summary Background Histologic remission in ulcerative colitis (UC) patients may be associated with positive outcomes. It is unclear whether UC patients in endoscopic remission obtain additional benefit from achieving histologic remission. Aim To evaluate the relationship between time to relapse and histological activity among UC patients in endoscopic remission. Methods In this retrospective study using an observational database, we identified UC patients who had achieved endoscopic remission (Mayo endoscopic subscore 0). Index colonoscopy was the first colonoscopy when endoscopic remission was achieved. Histologic activity was classified as normal, inactive or active colitis. The primary outcome was time to relapse. Secondary outcomes included reasons for relapse and the association between baseline variables and risk of relapse. A Cox proportional hazards model evaluated baseline factors and the outcome of relapse. Results We included 269 patients. The Kaplan‐Meier survival curve showed no significant difference between the presence or absence of histologic activity and time to relapse (log rank P = 0.85). There was no difference in time to clinical relapse of patients with histologically active colitis compared to inactive colitis (adjusted hazard ratio [AHR] 1.17, 95% CI 0.58‐2.32, P = 0.67]). 5‐aminosalicylate use (AHR 0.42, 95% CI 0.21‐0.82, P = 0.011), pancolitis (AHR 0.32, 95% CI 0.13‐0.75, P = 0.008), left‐sided colitis (AHR 0.46; 95% CI 0.22‐0.98; P = 0.044) and older age (AHR 0.96, 95% CI 0.94‐0.99, P = 0.002) were significantly associated with reduced time to clinical relapse. Conclusion Histologic remission did not influence time to relapse in UC patients who had achieved endoscopic remission.